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Live imaging of megakaryocytes from cranial bone 
marrow using multiphoton microscopy 
 
Abstract  
 
Platelet production is a tightly regulated process that occurs predominantly in the bone 
marrow. To study the biology of platelet precursor cells, megakaryocytes, we established a 
microscopy technique to visualize platelet production in live mice. This technique is now used to 
determine the role of Rap1, a small GTPase, in platelet production. Specifically, we monitor 
megakaryocyte proplatelet formation (PPF) in mutant mice for Rap1 and its regulator, Rasa3, in 
real time. With the videos collected, it is evident that the developed protocol was successful at 
capturing PPF in cranial BM of mice. The preliminary qualitative observations made from 
acquisition of these events in mutant mice help to support data made ex-vivo and better understand 
the role of Rap1 in platelet production. Compared to control, mice lacking both isoforms of Rap1, 
Rap1a and Rap1b, exhibited periods of proplatelet extension and retraction, suggesting a difficulty 
in proplatelet release from Mk cell body. Rasa3 mutant mice exhibited mutant Mk morphology, 
however, were still capable of PPF in BM sinusoids.  
 
 
Introduction  
  
Platelets are small anucleate cells that circulate in the bloodstream. These cells are 
important in hemostasis as they play a vital role in the clotting process. Through complex 
regulatory systems, platelets remain quiescent until they are exposed to different 
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microenvironmental conditions 
primarily triggered by vascular 
injury. During hemostatic plug 
formation, activated platelets go 
through a series of morphological 
and cellular changes that allow 
them to adhere to the extracellular 
matrix and to other platelets.  
Continuous production of 
platelets by their progenitor cells, 
megakaryocytes (Mks), is 
required to maintain a steady 
peripheral platelet count. Mks in humans produce roughly 1011 platelets a day.1 Hyperproduction of 
platelets can lead to thrombocytosis, a known risk factor for cardiovascular complications such as 
stroke or heart attack. On the contrary, impaired Mk function can lead to macro- or 
microthrombocytopenia, i.e. a reduction in the number of platelets produced associated with an 
increase or a decrease in platelet size. Often thrombocytopenia is associated with impaired platelet 
function and an increased risk for bleeding.  
Mks are primarily found in the bone marrow (BM), but recently it was shown that Mks 
also produce and release platelets in the lung.2 Megakaryopoeisis begins with hematopoietic stem 
cells and ends with mature Mks characterized by a highly polyploid nucleus, expanded size, 
extensive intracellular organelles, and biogenesis of a membrane structure called the demarcation 
membrane system (DMS). DMS formation is a crucial step during Mk maturation; this process 
Figure 1. Schematic of Mk PPF. The above schematic effectively 
demonstrates the steps by which PPF follows. Starting with 
localization and orientation to sinusoids, followed by podosome 
formation and matrix/basement membrane degradation by MMPs, 
ending with proplatelet extension into sinusoidal lumen and release 
into circulation.  
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creates a complex network of tubules and cisternae that are continuous with the plasma membrane. 
The structure allows for proplatelet formation (PPF), the final stage of Mk maturation. PPF is the 
formation of long pseudopod-like protrusions that extend into BM sinusoids, leading to the release 
of functional platelets into the bloodstream (Fig. 1).3  
With megakaryopoiesis being such a convoluted process, the microenvironments 
surrounding the Mks help direct proper Mk development. In the bone marrow, there are two main 
compartments that have different microenvironments: the osteoblastic niche and the vascular 
niche. The vascular niche, containing collagen type IV, fibronectin, fibrinogen and von Willebrand 
factor, creates an environment that promotes PPF. Once Mks are fully differentiated, they localize 
closer to the sinusoids and form proplatelets. Gradients for chemokines such as stromal-derived 
factor 1 (SDF-1) promote cellular orientation and directional PPF into sinusoids.4 With an 
established direction for PPF being formed, the next step is to successfully extend proplatelets 
through vessel endothelium and into the sinusoidal lumen. The degradation of BM extracellular 
matrix proteins and sinusoid basement membrane has been hypothesized to occur through the 
formation of podosomes, actin-rich cylindrical structures at the surface of Mk plasma membranes. 
Using matrix metalloproteinases (MMPs), specifically MMP-9, and myosin-IIA, podosomes help 
foster effective delivery of proplatelets into the bloodstream (Fig. 1).45 Once proplatelets have 
effectively extended into the sinusoidal lumen, they are exposed to blood shear forces that induce 
proplatelet release from the Mk cell body, leading to the formation of functional platelets 
circulating throughout the body.    
The Bergmeier Lab studies the role of the small GTPase Rap1 in platelet biology. Rap1 
has two isoforms, Rap1a and Rap1b, that play a critical role in platelet activation and regulation. 
In platelets, Rap1 activity is upregulated by a guanine nucleotide exchange factor (GEF), CalDAG-
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GEFI, and downregulated by the GTPase activating protein (GAP), Rasa3. Rasa3 restrains 
CalDAG-GEFI-dependent Rap1 activation, thus keeping Rap1 in its inactive, GDP-bound state. 
This ensures platelet quiescence in circulation. In order to ensure the sustained Rap1 activity 
needed to form a hemostatic plug, Rasa3 is turned off via P2Y12 signaling. Upon engagement of 
agonist receptors, intracellular signal transduction pathways stimulate the increase of cytosolic Ca2+ 
levels, creating a highly sensitive and fast integrin activation response mediated by CalDAG-
GEFI/Rap1 signaling. Rap1-GTP allows the adaptor protein, talin, to complex with the αIIbβ3 
integrin. The active conformation of αIIbβ3 binds fibrinogen and allows for platelet aggregation, a 
crucial step in the formation of a hemostatic plug (Fig. 2).67  
A recent publication from the Bergmeier Lab demonstrated that mice lacking both Rap1 
isoforms specifically in platelets and Mks exhibit a 50% reduced platelet count compared to 
control mice, increased platelet size and severe platelet dysfunction, leading to excessive bleeding.7 
The macrothrombocytopenia suggests that PPF is impaired in these mice. In an effort to better 
understand the PPF process by Mks, this paper has established a protocol to live image Mks in 
their native microenvironment. The protocol described in this paper allows us to effectively 
observe PPF in cranial BM of our mouse models using 2-photon microscopy. This protocol has 
allowed us to compare and contrast PPF across multiple mouse strains with defects in Rap1 
signaling.  
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Materials 
  
REAGENTS  
• Bacteriostatic 0.9% Sodium Chloride 
Solution (Hospira X69241)  
• Platelet Depletion Antibody, 0.5 mg/ml 
(Emfret R300)  
• GPIX488 Antibody (Emfret R300)   
• TRITC-Dextran MW 155,000 (Sigma-
Aldrich) 
• Ketamine HCL Injection (VetOne)  
• AnaSed Injection (Xylazine 100mg/mL)  
 
EQUIPMENT  
• Curved Scissors (Miltex 18-1398)  
• Forceps (World Precision Instruments 
504506)  
• Kimwipes (Kimtech Science Brand)  
• Insulin syringes, 1 ml 
• DI Water 
• Polyethylene tubing  
• LiquiVet Rapid Tissue Adhesive (VG3)  
• 14mm round cover glasses (Deckgläser 
0111540) 
• Metal frames  
• Adhesive Tape   
• Cotton- Tipped Applicators (Fisherbrand 
23-400-114)  
• Heating pad  
• Custom plexiglass skull immobilizing 
platform (Fig. 4)  
• Olympus Fluoview Multiphoton, 
Upright Microscope with 25X aqueous 
objective   
• Fluoview Software  
• FIJI ImageJ Software (Version 2.0)  
• Photoshop CC 2019 
  
Figure 3. Rap1a/b 
Isoform platelet 
counts and size. (a) 
Peripheral platelet size 
in control, Rap1a-/-, 
Rap1b-/- , and 
Rap1a/b-/- mice (n=9). 
(b) Peripheral platelet 
counts  in indicated 
mice.  
Figure 2. Rap1 mediating integrin activation 
in platelets. The schematic demonstrates how 
Rap1 is regulated by CalDAG-GEFI and Rasa3, 
which are directly and indirectly regulated by 
extracellular signaling of membrane bound 
proteins.   
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Procedure 
 
Mice: 2-3 month old mice weighing between 18-
22g were used. Mice with conditional Rap1a and 
Rap1b alleles (fl/fl) were crossed with C57BL/6 mice 
expressing Cre-recombinase under the platelet 
factor 4 promoter (PF4-Cre) to generate mice 
lacking expression of Rap1a and Rap1B in 
megakaryocytes and platelets 
(Rap1a/Rap1bfl/flPF4Cre; Rap1dKO). Hypomorphic 
Rasa3 mutant mice (Rasa3HLB; single amino acid 
substitution at position 794, H794L) were obtained 
from the Jackson labs. All mouse experiments were 
reviewed and approved by the Institutional Animal 
Care and Use Committee at the University of North 
Carolina at Chapel Hill. Mice were provided with 
food and water ad libitum. 
 
 
Mouse preparation before surgery 
 
1. ~66 hours before surgery, mice are injected by retro-orbital injection with 100 µl saline 
containing platelet depletion antibody (0.25 µg/ g of body mass) to render mice 
thrombocytopenic and ensure BM Mk labeling with antibody against GPIX (CD42a), a 
receptor specifically expressed on Mks and platelets.  
2. 18 hours later, mice are injected (retro-orbitally) with 20 µg (in a 100 µl saline solution) of anti 
GPIX-Alexa 488 antibody. Mice are left for 48 hours in order to ensure Mk saturation of 
antibody.    
 
Anesthetic Injection and Dextran  
 
3. The day of the surgery and imaging, a 10% Ketamine/1.5% Xylazine solution is injected 
intraperitoneally (10 µl/g of body mass) and mice are kept for 30 minutes in the cage before 
attempting toe-pinch. (See Table 1. for troubleshooting)  
4. TRITC-Dextran is used to visualize mouse vasculature during acquisition periods. Mice are 
injected with 100 µl of the 25 mg/ml solution via retro orbital injection.  
 
Equipment Setup *All equipment set up is done while the mouse is being anesthetized* 
 
6. Hardware, lasers and software are turned on (See Table 1. For troubleshooting)   
7. Multiphoton (MP) laser must be turned on through the Fluoview software so that it can warm 
up (at least 15 minutes)  
8. Objective (XL Plan N 25x/ 1.05 WMP) is attached to the microscope  
12 cm
8.5 cm
 4.5 cm
Heating Pad
Objective
Cover 
Slip
DI Water
Screw Anchor
Metal Frame 
Plexiglass Platforma. b.
Figure 4. Skull Immobilizing Platform Setup. 
(a) Above view of mouse set in skull 
immobilizing platform. (b) Acquisition set up 
with the microscope objective submerged in 
DI water and mouse secured in platform.   
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9. Channels are set to excite MKs (green) and 
vessels (red) separately. RXD2 (green) is set 
at a laser power of 35% and RXD4 is set at 
25%.  
 
Surgery 
 
10. Mice are tested to see if they are fully 
anesthetized through administration of a toe 
pinch (see Table 1. for troubleshooting)   
11. Due to long imaging times (90 min), mice 
must be kept at ~35-37 0 C using a heating 
pad8  
12. Cranial skin is removed to expose the skull. 
(Fig. 5 a9)  
13. Using surgical glue, the frame with cover 
slip is glued directly onto the skull along the 
sagittal suture between the bregma and 
lamda. The glue is left to set for ~2-4 minutes 
(Fig. 5 b10) (See Table 1. for troubleshooting)     
14. The frame and mouse are then fastened into 
the custom plexiglass platform in order to 
stabilize the skull.  
15. The mouse in the frame is placed under the objective and taped down to the stage  
16. Once mouse and stage are properly set up and ready for acquisition, an isoflurane nose cone is 
taped down to the mouse’s nose as constant anesthetic is required for the long acquisition 
periods  
17. 200 µl of DI water is added to the cover slip and the objective is submerged in the water  
(Fig. 4 b)   
 
Image Acquisition 
18. Epifluorescence is used to locate Mks and an appropriate imaging window  
19. Switching from epifluorescence to MP, focus and gain fine tuning is made to ensure proper 
resolution of Mks of interest. (see Table 1. for troubleshooting if MKs are not visible on 
computer)   
20. Acquisition time is between ~1-2 hours, depending on MK activity (see Table 1. For 
troubleshooting). Images are acquired on one focal plane at a rate of 1.33 image/min. The 
microscope used is owned by the Hooker Imagine Core at the University of North Carolina-
Chapel Hill.   
 
Image Exporting and Analysis 
21. Videos are saved as oib files and exported onto an external drive 
22. Files are exported as avi files using FIJI ImageJ so that all further changes can be made using 
Photoshop CC 2019  
 
 
a.
b. 
Figure 5. Surgery. (a) Area where skin is 
removed during surgery in order to expose the 
skull. (b) Skull anatomy depicting proper brace 
attachment location.  
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Table 1. Troubleshooting  
 
Step Problem  Solution 
3 and 10 Mouse not fully anesthetized  If after 30 minutes the mouse is not 
fully anesthetized, it should be 
injected with 5 µl/g of body mass of 
the 10% Ketamine solution 
intraperitoneally. Wait another 15 
minutes before assessing another 
toe pinch. Remember to use 
administer isoflurane during the 
image acquisition period.  
6 -Software is not allowing you to set 
up laser channels 
 
 
-Ensure that all indicator lights are 
on and green. If one is not, power it 
off and start again. If source of 
problem is unknown turn off all 
hardware and try again.  
13  -Glue is not securely attached to the 
skull 
 
-metal frame placed in wrong 
location.  
For either case, gently remove the 
frame and cover slip from the skull. 
With forceps, remove any excess 
glue remaining on the skull. With a 
syringe and a Kimwipe, rinse of the 
skull, patting it dry once clean. 
Reapply a new, clean frame.  
17 - “change light path to RXD” most 
likely appeared on the screen 
 
-or a black screen is all that can be 
seen 
-Make sure that the light path was 
manually changed on the 
microscope from FITC to RXD4 
 
-ensure that the manual eyepiece 
screen is pushed in 
18 -MK activity not observed  
-stage shifting is observed  
-in either case stop acquisition and 
use epifluorescence to either find 
new MKs or reset your position 
 
 
 
Results 
 
 This main goal of this project was to establish an effective method for imaging mouse BM 
megakaryocytes in live mice by two-photon microscopy. With the above protocol being 
established, we were able to effectively image Mks in cranial BM for extended periods of time, 
successfully capturing the PPF process as well. The following observations made from these 
videos serve as preliminary results that may support data generated ex-vivo or help raise questions 
that steer the direction of future experiments.   
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Proplatelet formation in Control mice  
 
 Control Mks seen in Figures 6 & 7 have a predominately spherical shape. The PPF process 
appears to begin with changes in Mk morphology, leading to less spherical and more pseudopodia-
like morphology (Fig. 6 & 7 a-d). Membrane rearrangement is visualized clearly through an 
increasing variety in the intensity of green fluorescence seen across the Mk highlighted in the blue 
circle (Fig. 6 a-d). Proplatelet extension through sinusoid endothelium and into the lumen appears 
to occur after roughly 20 minutes (Fig. 6 d-e). Post-entrance into sinusoids, proplatelets further 
elongate (Fig 6 f-g) as they are exposed to blood shear forces, eventually being released from the 
Mk (Fig. 6 h). The process in Figure 6 was acquired over a 150-minute time period. MK 
membrane and cytoskeletal rearrangement appeared to last until the 113-minute mark, when 
proplatelet transmigration across sinusoid endothelium begins (Fig 6. d). Extension through 
sinusoid visualized between image d and e in Figure 6 lasted approximately 19 minutes. 
Proplatelet extension and release lasted approximately 18 minutes (Fig. 6 e-h).         
 
 
Figure 6.  Visualization of wt Mks and PPF in cranial BM by two-photon microscopy. 150-minute acquisition 
time. (a-d) Blue circles outlining MK. (e-h) Blue arrows highlight proplatelet location.   
WT 
~150 min
~36 min   ~0 min ~72 min ~113 min
~138 min  ~132 min ~144 min
GPIX-488 
DEXTRAN
a. b. c. d.
e. f. g. h.
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 In figure 7, Mk membrane and cytoskeletal rearrangement occurred over 60 minutes (Fig. 
7 a-d). Proplatelet extension was not visualized during this acquisition as an already extended 
proplatelet entered the field of view at the 64-minute mark (Fig. 7 e). The highlighted proplatelet 
continued to extend for 26 minutes (Fig 7. e-h) and release was not observed. Image h in figure 7 
shows the potential formation of a second proplatelet beginning to extend alongside the original 
proplatelet being observed.   
 
Figure 7. Two-photon visualization of wt MKs and PPF in cranial BM. 90-minute acquisition time. (a-d) Blue 
circles outlining MK, highlighting morphological changes over time. (e-h) Proplatelet formation and extension into 
BM sinusoid (blue arrows).  
 
Proplatelet formation in Rap1-dKO mice  
 
 Mk rearrangement and proplatelet extension through the sinusoid had already occurred at 
the time acquisition began (Fig. 8 a). The highlighted proplatelet continued to extend further into 
the sinusoid for approximately 8 minutes (Fig. 8 a-b). After 8 minutes, the proplatelet began to 
retract back toward the site of entrance into the lumen, at the same time creating a bulbous end 
seen in figure 8 c-h. For the remaining 79 minutes, the proplatelet appeared to remain stagnant, 
WT
~20 min ~45 min ~60 min
~64 min    ~66 min    ~80 min    ~90 min
   0 min
GPIX-488 
DEXTRAN
a. b. c. d.
e. f. g. h.
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going through phases of short extension (Fig. 8 d, f) followed by retraction back to the site of 
entrance (Fig. 8 c, e, g-h).  
 Compared to controls, Rap1-dKO PPF exhibit notable differences. While there was an 
initial extension of a uniform proplatelet into the sinusoid, the observed retraction back towards 
the site on entrance was unique to the Rap1-dKO mouse. The apparent aggregation of membrane 
in the form of a bulbous end was another observable difference. 
 
Figure 8. Visualization of PPF in Rap1-dKO mice. 90-minute acquisition time. Blue arrows highlight proplatelet 
location.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rap1a -/- Rap1b-/- 
   0 min ~20 min ~45 min
~20 min
 ~8 min ~16 min ~24 min ~8 min ~11 min ~19 min
~34 min  ~24 min ~64 min ~78 min
~64 min   ~0 i  ~0 min
GPIX-488 
DEXTRAN
a. b. c. d.
e. f. g. h.
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Proplatelet formation in Rap1a-KO mice  
 
 
Figure 9. Visualization of Rap1a-KO proplatelets. 60-minute acquisition time. Blue arrows highlight proplatelet 
location.  
 
To analyze if and how the individual Rap1 isoform affect PPF, mice deficient in Rap1a or 
Rap1b were imaged. Proplatelet transmigration from the Mk cell body was not observed in the 60-
minute acquisition seen in Figure 9. Proplatelet extension is visualized over the 23-minute period 
depicted by images a-d in Figure 9. Proplatelet retraction and formation of a bulbous end was 
observed over the remainder of the 60-minute acquisition. Not effectively depicted in Figure 9 but 
observable in the attached video, is the spring-like nature in which retraction was also coupled 
with short periods of extension. Highlighted by the bottom blue arrow in images e-h of Figure 9, 
is the entrance of a different proplatelet inferior to the first proplatelet previously described.    
The observed PPF behavior in Rap1a mutant mice exhibited features of both control and 
Rap1-dKO mice. Initial extension of a uniform proplatelet deep into the sinusoid reflects the more 
WT behavior. The formation of a smaller bulbous end as well as a less significant retraction event 
back towards the site of entrance likens Rap1a-KO PPF to Rap1-dKO.  
Rap1a -/- 
   0 min ~20 min ~45 min
~20 min
~64 min  ~8 min   ~0 i ~16 min ~24 min ~8 min   ~0 min ~15 min ~23 min
~38 min  ~30 min ~48min ~55 min
GPIX-488 
DEXTRAN
a. b. c. d.
e. f. g. h.
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Proplatelet formation in Rap1b-KO mice  
 
 In Rap1b mutant mice, PPF extension is already observed at the time the acquisition began. 
The proplatelet seen in figure 10 a-c continues to extend its protrusion until it is no longer captured 
in the field of view, potentially due to proplatelet release into circulation. At roughly the 29-minute 
mark, a large membrane body continuous with the proplatelet observed and Mk enters the sinusoid. 
For the remaining 70 minutes, this protrusion goes through periods of short extension away from 
the Mk cell body followed by immediate retraction back (Fig 10 d-h).  
 
 
Figure 10. Visualization of Rap1b-KO proplatelets. 60-minute acquisition time. Blue arrows highlight proplatelet 
location.  
 
Rap1b PPF appears to exhibit behavior that more closely resembles that of Rap1-dKO PPF. 
There was an initial extension of a proplatelet into the sinusoid that may have been released as it 
was lost during the acquisition. The large membrane body that is observed afterwards exhibits the 
same behavior of short extension and retraction as seen in Rap1-dKO PPF.  
 
Rap1b-/-
 ~8 min   ~0 min ~16 min
a. b. c. d.
e. f. g. h.
GPIX-488 
DEXTRAN
~100 min
~6 min   ~0 min ~15 min ~29 min
~65 min  ~47 min ~85 min
 14 
 
Proplatelet formation in Rasa3hlb/hlb mice  
 
 Rasa3HLB/HLB Mks have a highly convoluted morphology that is less spherical in shape. The 
presence of increased membrane artifacts in the BM matrix is also observed in figure 11.  The 
proplatelet highlighted by the blue arrow in image a of figure 11 exhibits the same bulbous shape 
previously described. This proplatelet is released shortly after the beginning of acquisition as it is 
no longer observed in image b of figure 11.  
 Short Mk membrane artifacts appear to enter the sinusoid during the first 22 minutes of the 
60-minute acquisition (Fig. 11 a-d). Proplatelet extension occurred at the 30-minute mark and 
continued until the end of acquisition (Fig. 11 e-h). Not observable in figure 11 but visible in the 
attached video is the continued supply of membrane by Mk cell body leading to continued 
proplatelet extension and immediate release.   
 The PPF of Rasa3HLB/HLB  Mks does not reflect behavior similar to that of control or any Rap1 
mutant mice. The formations of multiple textured proplatelets that appear to continually release 
into the sinusoid is a unique observation. As these mice are characterized by a very rapid turnover 
of circulating platelets, this fast release of platelets from Mks may be a compensatory mechanism.   
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Figure 11. Rasa3HLB/HLB PPF. 60-minute acquisition time. Blue arrows highlight proplatelet location.  
 
 
Discussion 
 
 The development of this protocol began by exploring BM Mk visualization by shaving an 
acquisition window in the tibia. Cranial BM Mks proved to be a worthy substitute as the surgery 
is far less intensive and the imaging yields superior visualization of Mks. Experiments were 
conducted in order to determine how to maximize fluorescence labeling of Mks with the use of 
monoclonal antibodies. It was determined that platelet depletion prior to antibody injection 
markedly improved Mk labeling, likely due to the fact that the majority of the anti-GPIX antibody 
binds to circulating platelets first and Mks second. The protocol advanced through the construction 
of a platform that stabilizes the skull, allowing for smooth video acquisition over extended periods 
of time. Replacing aqueous gel applied directly to the skull by the current method involving a 
cover slip and DI water was another step that greatly improved the quality of the acquired images. 
The development of this protocol extended over a 5-month period and has now allowed us to 
~35 min  ~30 min ~44min ~52 min
Rasa3 HLB/HLB 
~64 min   ~0 i  ~0 min
GPIX-488 
DEXTRAN
a.
   0 min
 ~8 min ~5 min
b.
~20 min
~16 min~14 min
c.
~20 min
~24 min~22 min
d.
e. f. g. h.
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compare and contrast the differences in PPF across the various mouse strains with defects in Rap1 
signaling.  
Visualization of Mk PPF in cranial BM has provided valuable insight into how this process 
is altered in mice defective in Rap1 signaling. While these observations are preliminary, it is worth 
noting a few key differences and similarities that were seen across genotypes.  
By observing PPF in control mice, a clear sequence of events can be followed leading up 
to proplatelet release into the bloodstream. First, Mk membrane rearrangement, likely caused by 
cytoskeletal changes, leading to Mk shape change from spherical to more pseudopod-like. Second, 
nascent proplatelet like protrusions penetrate across sinusoidal endothelium, facilitating contact of 
protrusions with blood. Lastly, PP elongation, driven by blood shear forces, and release of 
proplatelets into the blood stream. 
All mutant mice observed in this paper exhibited PPF to some degree. Large, bulbous 
membrane bodies at the end of proplatelets as well as repeated periods of short proplatelet 
extension and retraction were primarily observed in the Rap1-dKO and Rap1b-KO genotypes. This 
defect in PPF is consistent with the macrothrombocytopenia observed in Rap1-dKO mice, and 
alterations in PPF seen in vitro (not shown).  
 Rap1a-KO Mks were also visualized as being capable of producing proplatelets. The 
observed proplatelets exhibited behavior between what was observed in control and Rap1-dKO 
mice, demonstrating less significant periods of extension and retraction back towards the site of 
entrance. A smaller bulbous end was also formed during the initial retraction event. In murine 
platelets, Rap1a is expressed at 10% of the level of Rap1b; if this ratio is the same in MKs, it would 
suggest that loss of Rap1a may have a lesser impact in PPF due its lower expression level. 
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However, our ex vivo studies suggest that Rap1a plays a more important role in MK proliferation 
than in PPF.7  
 Rasa3HLB/HLB Mks are particularly interesting as their morphology is quite different from 
control Mks. The less spherical, more convoluted structure of these Mks did not prevent PPF from 
happening. However, my studies suggest that the process is different from that in both control and 
Rap1 Mks. The proplatelets extended into the lumen of sinusoids depicted in figure 11 appear to 
have a more textured appearance and do not exhibit the bulbous end seen in both control and Rap1 
mutant proplatelets. These proplatelets also appear to release at a much faster rate. The extremely 
low platelet count observed in these mice may be due to the production of defective platelets that 
are immediately cleared by the body. 
 In conclusion, visualization of BM Mks using 2-photon microscopy allowed us to capture 
PPF in control, Rap1-dKO, Rap1a, Rap1b and Rasa3 mutant mice. Rap1-dKO, Rap1a and Rap1b 
mice exhibited PPF behavior that suggests an inability to release platelets at the same rate as 
control while Rasa3 PPF suggested the production of ineffective platelets that are immediately 
cleared by the body. With the videos collected, it is evident that the developed protocol was 
successful at capturing PPF in cranial BM of mice. One limitation of these preliminary studies is 
the small number of PPF events that have been visualized. More acquisitions are required in order 
to obtain enough individual PPF events to make definitive conclusions about each genotype. 
Future considerations for this protocol include the visualization of other mutants, including 
CalDAG-GEFI knockouts. Temporal quantification of Mk morphology changes, PPF and release 
should be also considered. Methods that can effectively measure Mk size and proplatelet length 
could also help provide valuable, quantifiable data that can serve to support conclusions made 
from qualitative observations.   
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